Anavex Life Sciences Corp Sustainability Reports
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders. The company's lead drug candidates target sigma-1 and muscarinic receptors to address conditions such as Alzheimer's disease, Parkinson's disease, and Rett syndrome.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300K1I5L8COCQ8W36
FIGI: BBG001SLQWW6
1 reports from 2024 to 2024
